|Bid||0.0000 x 800|
|Ask||0.0000 x 900|
|Day's Range||2.0600 - 2.1400|
|52 Week Range||1.7000 - 36.2500|
|Beta (3Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.60|
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an additional $3.7 million. The increase in funding is primarily directed toward a Phase 1b clinical trial of NasoShield to evaluate alternative methods of intranasal dosing in humans. In 2018, BARDA awarded Altimmune $2.5 million for further NasoShield development including a comparison of different methods of administration of the vaccine in preclinical models.
GAITHERSBURG, Md., Aug. 13, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months.
GAITHERSBURG, Md., Aug. 05, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating.
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). The number of shares to be issued was determined based on the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty consecutive trading days prior to and including July 8, 2019, the date the definitive agreement was signed. Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies.
The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.
The deal puts Spitfire’s flagship product candidate — a treatment for nonalcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.
The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.
Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...
Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH. Altimmune will make an upfront payment of $5 million to Spitfire shareholders, who will also be eligible to receive an additional $8 million in regulatory and clinical milestones and up to $80 million in sales-based milestones. The deal is expected to close in July. Spitfire's NASH product candidate SP-1373 will be renamed ALT-801. "Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease," said Altimmune Chief Executive Vipin Garg. Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.
Company to conduct conference call on Tuesday, July 9, 2019 at 8:30 a.m. GAITHERSBURG, Md., July 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to be a valuable member of our senior leadership team since he stepped into the CFO role over a year ago,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer.
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial design and manufacturing plans for HepTcell. The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of Phase 2 trials. Altimmune intends to conduct a Phase 2 study in the United States and the pre-IND meeting was held to obtain feedback from the FDA on our intended development path.
Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual property protection with the additional patents covering our development candidates, HepTcell and ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. For HepTcell, the Company has been granted U.S. Patent No. 10,300,132 entitled “Vaccines Against Hepatitis B Virus.” The patent, which expires in 2035 accounting for 515 days of patent term adjustment, provides important additional IP protection for the HepTcell clinical development program, an immunotherapeutic being developed for patients chronically infected with the hepatitis B virus (“HBV”).
GAITHERSBURG, Md., May 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended.
GAITHERSBURG, Md., May 08, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel at 12:55pm Eastern Time. Dr. Sybil Tasker, Chief Medical Officer of Altimmune, will present data from the Company’s Phase 2 study and the recently completed Phase 2 extension study for NasoVAX.
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30:00 AM Eastern ...
GAITHERSBURG, Md., April 01, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December.
GAITHERSBURG, Md., March 21, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.
Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination.
GAITHERSBURG, Md., March 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million. On March 8, 2019, the Company disclosed approximately $34.4 million in cash, cash equivalents and restricted cash as of December 31, 2018. Altimmune intends to use the cash on hand together with the net proceeds of approximately $12.7 million from this offering for the continued advancement and development activities for its product pipeline, strategic growth opportunities (including potential acquisitions and/or licensing transactions), and general working capital purposes.